Showing 20 of 173 recruiting trials for “squamous-cell-carcinoma-of-the-hypopharynx”
Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
👨⚕️ Feng Wang, phD, The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2023View details ↗
A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.
RecruitingNCT05884983 ↗
Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
RecruitingNCT05858385 ↗
Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients
🏥 Affiliated Cancer Hospital & Institute of Guangzhou Medical University📍 1 site📅 Started Sep 2022View details ↗
SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
Optimization of Cervical Nodal CTV for Early and Medium Stage NPC
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
RecruitingNCT05392413 ↗
Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
👨⚕️ Lei Zheng, Nanfang Hospital, Southern Medical University📍 1 site📅 Started Aug 2022View details ↗
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
👨⚕️ Xiaolin MM GE, The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Jul 2022View details ↗
RecruitingNCT05707819 ↗
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
👨⚕️ Xiao-Dong Zhu, Doctor, Cancer Hospital of Guangxi Medical University📍 1 site📅 Started Jul 2022View details ↗
Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →